Plasma levels of soluble Fas (sFas) are elevated in human immunodeficiency virus type 1 (HIV-1) infection, indicating dysregulation of the Fas apoptosis pathway and chronic immune activation. We performed a retrospective study to investigate the effects of HAART on plasma levels of sFas. A cross-sectional study of 27 drug-naive infected subjects and 49 patients under antiretroviral treatment showed that plasma levels of sFas were higher in HIV-1-infected subjects than in 52 HIV-1-negative controls, independently of the treatment status. In a longitudinal study of 69 patients undergoing HAART, we observed a minimal, but significant decrease in sFas plasma levels after 1 year of therapy. Levels of sFas, however, remained still higher than physiologic values. Patients undergoing HAART were further classified as nonresponders or responders on the basis of viremia suppression; no significant changes in plasma levels of sFas were observed between the two groups. These findings show that 1 year of HAART has a minor effect on the sFas levels in plasma. Long-term HAART may be required to normalize the dysregulation of the Fas apoptotic pathway and the persistent immune activation initiated by HIV-1.
Scheda prodotto non validato
Scheda prodotto in fase di analisi da parte dello staff di validazione
|Titolo:||High plasma levels of soluble Fas in HIV type 1-infected subjects are not normalized during highly active antiretroviral therapy|
|Rivista:||AIDS RESEARCH AND HUMAN RETROVIRUSES|
|Citazione:||DE MILITO, A., Hejdeman, B., Albert, J., Aleman, S., Sonnerborg, A., Zazzi, M., et al. (2000). High plasma levels of soluble Fas in HIV type 1-infected subjects are not normalized during highly active antiretroviral therapy. AIDS RESEARCH AND HUMAN RETROVIRUSES, 16, 1379-1384.|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto: